Glenmark Generics, USA the subsidiary of Glenmark Generics has been granted final abbreviated new drug approval (ANDA) from the US FDA for Desoximetasone Ointment USP, 0.25 per cent their generic version of Topicort by Taro Pharmaceuticals USA and shipping will commence immediately.
Desoximetasone ointment is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. According to IMS Health sales data for the 12 month period ending June 2013, Desoximetasone ointment garnered annual sales of approximately $ 40 million.
Glenmark’s current portfolio consists of 89 products authorised for distribution in the US marketplace and 54 ANDA’s pending approval with the US FDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.
EP News Bureau – Mumbai